Bailard’s Tourmaline Bio TRML Stock Holding History

Bailard’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,477	Closed	-$41.5K	–	813
2023 Q3	$41.5K	Hold	1,477	–	–	﹤0.01%	692
2023 Q2	$44.9K	Hold	1,477	–	–	﹤0.01%	678
2023 Q1	$27.8K	Buy	+1,477	New	+$24.4K	﹤0.01%	710

Other funds holding TRML

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

QUSVM

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Bailard's TRML Position: Q4 2023 in Review

Bailard sold out of Tourmaline Bio (TRML) in Q4 2023, closing a stake of 1,477 shares — an estimated $41.5K sold.

Bailard first reported a position in TRML in Q1 2023 and held it in 3 quarters. The position peaked at $44.9K in Q2 2023. 54 funds tracked by Wall St. Rank hold TRML as of Q4 2023.

Bailard reported no remaining Tourmaline Bio position as of Q4 2023 after selling out during the quarter.
Bailard sold 1,477 Tourmaline Bio shares in Q4 2023, an estimated $41.5K.
Bailard first reported a position in Tourmaline Bio in Q1 2023 and held it in 3 quarters.
Bailard's Tourmaline Bio position peaked at $44.9K in Q2 2023.
54 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2023.

Based on Bailard's 13F filing for Q4 2023, filed 2 Feb 2024.